Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6508991 | 0.81 | PARP1 (0.44) | PARP1 | |
| SCHEMBL6529957 | 0.79 | PARP1 (0.37) | PARP1 | |
| SCHEMBL6512957 | 0.78 | KDM4E (0.43) | — | |
| SCHEMBL6508753 | 0.78 | CHEK1 (0.47) | PTGS2 | |
| SCHEMBL6046806 | 0.78 | IDH1 (0.36) | — | |
| SCHEMBL6511000 | 0.77 | PTGS2 (0.46) | PARP1PTGS2 | |
| SCHEMBL6523130 | 0.75 | ATR (0.44) | — | |
| SCHEMBL6509023 | 0.73 | CHEK1 (0.57) | — | |
| SCHEMBL6510843 | 0.73 | CHEK1 (0.47) | PARP1 | |
| SCHEMBL176777 | 0.72 | DGAT2 (0.37) | DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | DRD1 4838/4885PARP1 1091/4885PTGS2 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.